Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07646652 · ClinicalTrials.gov registry record
Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease
A clinical trial, sponsored by Stanford University.
- Not yet
- Registry status
- 40
- Enrollment target
NCT07646652: Clinical Trial study, sponsored by Stanford University.
NCT07646652 is a clinical trial that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07646652 has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- 40 participants
- Enrollment target
Study Summary
The goal of the study is to assess if learning one's Lewy Body Dementia (LBD) biomarker test result impacts longitudinal psychosocial and behavioral responses and to identify factors that moderate and mediate these outcomes.
Interventions
- OTHER LBD Biomarker Education and Disclosure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-11 |
| Est. Completion | 2030-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07646652
The ClinicalTrials.gov registry entry for NCT07646652 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBD Biomarker Education and Disclosure is the first listed.
NCT07646652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07646652 about?
NCT07646652 is a clinical study titled "Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease". The goal of the study is to assess if learning one's Lewy Body Dementia (LBD) biomarker test result impacts longitudinal psychosocial and behavioral responses and to identify factors that moderate and mediate these outcomes.
What is the current status of trial NCT07646652?
This trial is currently not yet recruiting. The enrollment target is 40 participants. The study started on 2026-11. Estimated completion is 2030-11.
What interventions are being tested in trial NCT07646652?
The interventions under investigation include: LBD Biomarker Education and Disclosure (OTHER).
Who is sponsoring clinical trial NCT07646652?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.